forty-eight patients with metastatic breast cancer previously treated with cytostatics ( except anthracyclines ) underwent peroral treatment with 4-demethoxydaunorubicin ( 4-dmdr ) , a new daunorubicin analogue .
C0020789
4-dmdr
C0011015
daunorubicin